Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report

Clicks: 263
ID: 272965
2021
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #3 of 5 articles by views in Annals of coloproctology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
With the advent of checkpoint inhibitors, it has opened up opportunities for numerous cancer patients. However, as is the case with every treatment, complications need to be weighed. Gastrointestinal adverse effects, such as diarrhea and colitis are well-known complications for checkpoint inhibitors …
Reference Key
hj2021annalscolonic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cho HJ;Kim WR;Kim JH;Kim DH;Kim DJ;Kang H;;
Journal Annals of coloproctology
Year 2021
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/34167190
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine case reports pmid:34167190 pmc8359691 doi:10.3393/ac.2020.00213.0030 hye jung cho woo ram kim haeyoun kang

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.